| Business: |
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”—French for illuminate—and “immunis”—Latin for the immune system.
We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE) for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024.
We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects.
Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction.
Note: Net loss and revenue are for the 12 months that ended March 31, 2024.
(Note: Alumis Inc. priced its IPO at $16.00 – the low end of its $16.00-to-$18.00 range – and downsized its IPO to 13.125 million shares – down from 17.65 million shares in the prospectus – to raise $210.0 million on Thursday night, June 27, 2024. Alumis also announced that it has agreed to sell an additional 2.5 million shares of its common stock in a concurrent private placement at $16.00 per share to one of its existing investors, AyurMaya Capital Management Fund, LP, to raise $40.0 million. Alumis Inc.’s combined gross proceeds from the IPO and the concurrent private placement are $250.0 million.)
(Background: Alumis Inc. filed its S-1/A on June 24, 2024, and disclosed the terms for its IPO: The company is offering 17.65 million shares at a price range of $16.00 to $18.00 to raise $300.05 million. Background: Alumis Inc. filed its S-1 on June 7, 2024, without disclosing terms for its IPO.)
|
